Author:
Yuan Haixia,Cao Yingying,Yu Zhenjun,Huang Yue,Liu Fang,Gao Yanying,Qiu Shaotian,Han Tao
Abstract
Abstract
Background
There are few studies on acute-on-chronic liver failure (ACLF) in patients with recompensated cirrhosis. This study was aimed to investigate the clinical features of ACLF patients with recompensated cirrhosis.
Methods
A total of 461 ACLF patients were enrolled and divided into three groups: compensated, recompensated, and decompensated cirrhosis with ACLF. The baseline clinical data and 1-year survival rates were compared among the three groups.
Results
Compared with the decompensated group, in the recompensated group, the levels of hemoglobin, albumin, and serum sodium were significantly higher and the white blood cell count, international normalized ratio, and incidence of respiratory failure were significantly lower; there were no evident differences in other organ failures. The proportion of patients with ACLF grade 3 and 1-year survival rates significantly differed between the two groups. Conversely, compared with the compensated group, in the recompensated group, the platelet and total bilirubin levels were significantly lower and the proportion of patients with ACLF grade 1 was significantly higher. However, other clinical indicators or 1-year survival rates did not significantly differ between the two groups.
Conclusions
Compared with patients who developed ACLF with decompensated cirrhosis, those who developed ACLF with recompensated cirrhosis had a less severe condition, lower incidence of respiratory failure, and better 1-year prognosis. However, the baseline clinical features and prognosis were similar between ACLF patients with recompensated and compensated cirrhosis.
Trial registration
Chinese clinical trials registry: ChiCTR1900021539.
Funder
the National 13th 5-Year Plan for Hepatitis Research
Publisher
Springer Science and Business Media LLC
Subject
Gastroenterology,General Medicine
Reference19 articles.
1. He ZY, Wang BQ, You H. Reversal of cirrhotic decompensation: recompensation. Chin J Hepatol. 2019;27(12):915–18.
2. Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of cirrhosis. J Clin Hepatol. 2019;27(11):846–65.
3. Monteiro S, Grandt J, Uschner F, Kimer N, Madsen J, Schierwagen R, et al. Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. Gut. 2021;70(2):379–87.
4. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-37,1437e1-9.
5. Bihari C, Anand L, Rooge S, Kumar D, Saxena P, Shubham S, et al. Bone marrow stem cells and their niche components are adversely affected in advanced cirrhosis of the liver. Hepatology (Baltimore MD). 2016;64(4):1273–88.